Pharmaceuticals
US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL
* Investigational new drug (IND) approval received by QBiotics, to initiate a Phase II clinical trial investigating tigilanol tiglate in the treatment of patients with Soft Tissue Sarcoma (STS) * The open label trial will evaluate efficacy and dose ranging in patients with advanced or metasta...
2022-07-25 07:09
3540
Congratulations! Kexing Biopharm (688136.SH) was awarded by the" Annual Top 20 Chinese Biopharmaceutical Entreprises"
SHENZHEN, China, July 21, 2022 /PRNewswire/ -- On 12 July 2022, Menet held the award ceremony of the "Annual Top 100 China's Pharmaceutical Entreprises in 2021", in which 5 sub-lists of the pharmaceutical industries had been announced. This event showcased the professionalism and influence of the...
2022-07-21 22:32
4752
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
– Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication – – Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) inMay 2022 – NEWTON, Mass. and FLORENCE, Italy, July 21, 2022 /PRNewswire/ -- Karyopha...
2022-07-21 21:25
4465
Telix Reports Second Quarter 2022 Financial Results
MELBOURNE, Australia, July 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended30 June 2022. All figures are in AUD$ unless otherwise stated. All fi...
2022-07-21 08:34
3559
VIRALEZE™ Nasal Spray Protects Against Highly Infectious Omicron in Viral Challenge Model - Before or After Viral Exposure
MELBOURNE, Australia, July 20, 2022 /PRNewswire/ -- Starpharma's broad-spectrum VIRALEZE™ nasal spray has shown protection against infection with the highly transmissible SARS-CoV-2 Omicron variant in a stringent viral challenge model. VIRALEZE™ is a broad-spectrum barrier nasal spray, developed ...
2022-07-20 17:45
2737
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
SAN FRANCISCO, ROCKVILLE, Md. and SUZHOU, China, July 20, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ...
2022-07-20 08:00
3909
U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older
* Recommendation follows U.S. FDA Emergency Use Authorization for the Novavax COVID-19 Vaccine, Adjuvanted as a two-dose primary series * FDA has determined that first vaccine lot has met all release specifications and is acceptable for use underEmergency Use Authorization * Novavax expects ...
2022-07-20 05:46
3637
Seegene launches world's first In-life PCR campaign in Vietnam
* Test center LabHouse and ride-hailing service Grab to start PCR testing for Grab drivers in August * Seegene to provide Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay to simultaneously detect COVID-19, flu, cold * Testing to begin with drivers in Ho Chi Minh, Hanoi and will later be expanded to ...
2022-07-19 18:43
2578
Oncoshot Enters Collaboration Agreement With Omico (Australian Genomic Cancer Medicine Centre)
SINGAPORE, July 19, 2022 /PRNewswire/ – Oncoshot has just entered into a collaboration agreement with Omico, the Australian Genomic Cancer Medicine Centre. The respective parties were represented at the event yesterday by Dr Huren Sivaraj, CEO and co-founder of Oncoshot, and Prof David Thomas, ...
2022-07-19 18:30
3274
WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapore
* This investment will establish a cutting-edge, fully integrated CRDMO center inSingapore, including a research and development service center and large-scale drug substance and drug product manufacturing facilities for biologics * The investment strengthens WuXi Biologics' global research, ...
2022-07-19 18:03
3623
Guo Guangchang Visits Fosun's Member Companies in Hamburg, Germany and Meets Carola Veit, President of Hamburg Parliament
HONG KONG, July 19, 2022 /PRNewswire/ -- On 18 July 2022, Mr. Guo Guangchang, Chairman of Fosun International, and his delegation visited Yuyuan inHamburg, and German lifestyle fashion brandTom Tailor. He also met and had lunch with Ms. Carola Veit, President of the Hamburg Parliament. Mr. Marco W...
2022-07-19 15:55
5316
Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment inChina, evaluated through a rand...
2022-07-19 12:34
5065
Significant Glycemic Control and Weight Loss: Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, July 19, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and o...
2022-07-19 08:00
5176
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics
Kinpeygo® (developed under the name NEFECON) is the first and only EMA- approved treatment for IgAN Everest Medicines has exclusive rights to develop and commercialize NEFECON in Greater China, Singapore and South Korea SHANGHAI, July 18, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Ev...
2022-07-18 08:00
4811
Amaris B. Clinic Is Seeing More Patients for Liposuction Due To Inefficacy of Non-surgical Fat Reduction Treatments
Dr Ivan Puah, Medical Director at Amaris B. Clinic, has been performing modern liposuction and corrective surgeries for patients who have experienced less than satisfactory results from non-surgical treatments and those who suffer from PAH, a rare side effect of cryolipolysis. SINGAPORE, Ju...
2022-07-17 10:42
4542
CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China
* GAVRETO is the first highly selective rearranged during transfection (RET) inhibitor approved inHong Kong, China for the treatment of RET fusion-positive metastatic non-small cell lung cancer * GAVRETO is CStone's second therapy approved in Hong Kong, China * GAVRETO is CStone's ninth NDA ...
2022-07-15 08:02
5068
Oncoshot Receives Funding To Expand Cancer Data Sharing Capabilities For Hospitals and Industry
SINGAPORE, July 14, 2022 /PRNewswire/ -- Oncoshot today announced a pre-series A funding round led by MassMutual Ventures (MMV). Other investors for this stage come from a suite of healthtech veterans that include Milltrust International and health industry angel investors. This funding wi...
2022-07-14 15:30
3758
GenScript ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel Drugs
SEOUL, South Korea, July 14, 2022 /PRNewswire/ -- On the July 14, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and DAAN Bio Therapeutics (Byoung Chul Cho, Co-Founder & CEO), an innovative new drug developer such as antibody treatments and cell therapy drugs, announced that the...
2022-07-14 13:00
3548
Triastek announces research collaboration with Lilly to explore the application of 3D printing technology in oral delivery of drugs
NANJING, China, July 14, 2022 /PRNewswire/ -- On July 13, 2022, Triastek, Inc. ("Triastek") announced a collaboration with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company, to leverage the advantages of 3D printing technology to enable precisely targeted and programmed rel...
2022-07-14 09:00
4212
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
* Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. * Immunizations with the Novavax COVID-19 Vaccine, Adjuvanted as a primary series will begin upon product release and once a policy recommendation from the CDC is received GAITHERSBURG, Md., July 14, 2022 /P...
2022-07-14 06:06
4384
Week's Top Stories
Most Reposted
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
OGA 2026 OPENS WITH STRONGER FOCUS ON MARKET ACCESS, REGIONAL PROJECTS AND ENERGY OPPORTUNITIES
[Picked up by 276 media titles]
2026-09-04 01:35
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 271 media titles]
2026-09-09 13:26
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
[Picked up by 266 media titles]
2026-09-07 13:00
People See One Brand. The Internet May Show Them Hundreds More.
[Picked up by 264 media titles]
2026-09-07 09:00Most Read
FinVolution and NUS Business School share project findings focusing on Financial Inclusion for Filipino Overseas Domestic Helpers at UN Global Compact BRI Summit
2026-09-04 13:11
10399
Physical AI Firm XTEND Set to Make NYSE Trading Debut: NYSE Content Update
2026-09-04 21:14
9535
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
2026-09-04 10:43
7209
DAHON TECH Announces 2026 Interim Results; Revenue and Profit Record Strong Growth
2026-09-04 16:09
6594